{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T19:25:55Z","timestamp":1780860355484,"version":"3.54.1"},"reference-count":78,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.3892\/etm.2017.4210","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T08:55:46Z","timestamp":1489049746000},"page":"1977-1985","source":"Crossref","is-referenced-by-count":6,"title":["Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and \u03b2-blocker combination therapy vs. \u03b2-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis"],"prefix":"10.3892","volume":"13","author":[{"given":"Jianrong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Yong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"key20180108134418_b1-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(95)91740-3","article-title":"Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis","volume":"346","author":"Feu","year":"1995","journal-title":"Lancet"},{"key":"key20180108134418_b2-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0016-5085(90)91168-6","article-title":"Haemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage","volume":"99","author":"Groszmann","year":"1990","journal-title":"Gastroenterology"},{"key":"key20180108134418_b3-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMra0901512","article-title":"Management of varices and variceal hemorrhage in cirrhosis","volume":"362","author":"Garcia-Tsao","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180108134418_b4-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology"},{"key":"key20180108134418_b5-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hep.1840190506","article-title":"Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis","volume":"19","author":"Garcia-Pag\u00e1n","year":"1994","journal-title":"Hepatology"},{"key":"key20180108134418_b6-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"key20180108134418_b7-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J Hepatol"},{"key":"key20180108134418_b8-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3748\/wjg.14.1908","article-title":"Haemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial","volume":"14","author":"De","year":"2008","journal-title":"World J Gastroenterol"},{"key":"key20180108134418_b9-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1572-0241.2007.01759.x","article-title":"Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: A placebo-controlled, double-blind study","volume":"103","author":"Schepke","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key20180108134418_b10-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/jhep.2003.50032","article-title":"Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study","volume":"37","author":"Abecasis","year":"2003","journal-title":"Hepatology"},{"key":"key20180108134418_b11-etm-0-0-4210","first-page":"567","article-title":"Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: A meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"key20180108134418_b12-etm-0-0-4210","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: A meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"key20180108134418_b13-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"key20180108134418_b14-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research","volume":"163","author":"Gluud","year":"2006","journal-title":"Am J Epidemiol"},{"key":"key20180108134418_b15-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key20180108134418_b16-etm-0-0-4210","first-page":"145","article-title":"Haemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension","volume":"21","author":"Sen","year":"2002","journal-title":"Indian J Gastroenterol"},{"key":"key20180108134418_b17-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MEG.0b013e3283455b7f","article-title":"Effects of treatment with \u03b2-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosis","volume":"23","author":"Winkler","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20180108134418_b18-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1572-0241.2003.07497.x","article-title":"Portal pressure response to losartan compared with propranolol in patients with cirrhosis","volume":"98","author":"De","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key20180108134418_b19-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1665-2681(19)32156-8","article-title":"A randomized study of losartan vs propranolol: Effects on hepatic and systemic haemodynamics in cirrhotic patients","volume":"2","author":"Castano","year":"2003","journal-title":"Ann Hepatol"},{"key":"key20180108134418_b20-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/1751-2980.12025","article-title":"Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease","volume":"14","author":"Agasti","year":"2013","journal-title":"J Dig Dis"},{"key":"key20180108134418_b21-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2007.01.017","article-title":"AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers","volume":"46","author":"Debernardi-Venon","year":"2007","journal-title":"J Hepatol"},{"key":"key20180108134418_b22-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/gast.2001.26288","article-title":"Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis","volume":"121","author":"Gonzalez-Abraldes","year":"2001","journal-title":"Gastroenterology"},{"key":"key20180108134418_b23-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0168-8278(02)00443-9","article-title":"Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: Comparison with propranolol in a randomised controlled study","volume":"38","author":"Venon","year":"2003","journal-title":"J Hepatol"},{"key":"key20180108134418_b24-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/hep.510230517","article-title":"The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites","volume":"23","author":"Nevens","year":"1996","journal-title":"Hepatology"},{"key":"key20180108134418_b25-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.3748\/wjg.14.6824","article-title":"Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients","volume":"14","author":"Vilas-Boas","year":"2008","journal-title":"World J Gastroenterol"},{"key":"key20180108134418_b26-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0168-8278(01)00307-5","article-title":"Lebrec D, Poynard T, Hillon P, Benhamou J-P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. A controlled study [N Engl J Med 1981;305:1371-1374]","volume":"36","author":"Pagliaro","year":"2002","journal-title":"J Hepatol"},{"key":"key20180108134418_b27-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2013.11.019","article-title":"Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: A multicentre randomized controlled trial","volume":"60","author":"Shah","year":"2014","journal-title":"J Hepatol"},{"key":"key20180108134418_b28-etm-0-0-4210","first-page":"57","article-title":"Correction of portal hypertension by beta-adrenoblockers (atenolol and metoprolol) and inhibitors of ACE (lisinopril and enalapril) in liver cirrhosis","author":"Lazebnik","year":"2007","journal-title":"Eksp Klin Gastroenterol"},{"key":"key20180108134418_b29-etm-0-0-4210","first-page":"171","article-title":"Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy","volume":"53","author":"Wagatsuma","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"key20180108134418_b30-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-003-1222-8","article-title":"Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity","volume":"38","author":"Baik","year":"2003","journal-title":"J Gastroenterol"},{"key":"key20180108134418_b31-etm-0-0-4210","first-page":"669","article-title":"Medicinal influence on portal vein haemodynamics by cirrhosis of the liver-comparison between angiotensin II receptor antagonists and \u03b2-blockers in combination with spironolactone","volume":"39","author":"Klein","year":"2001","journal-title":"J Zeitschrift fur Gastroenterologie"},{"key":"key20180108134418_b32-etm-0-0-4210","first-page":"881","article-title":"Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study","volume":"43","author":"Alessandria","year":"2011","journal-title":"Dig Liver Dis"},{"key":"key20180108134418_b33-etm-0-0-4210","first-page":"202","article-title":"Rifaximin improves the treatment of hepatic encephalopathy","volume":"17","author":"Block","year":"2010","journal-title":"J Clin Outcomes Manage"},{"key":"key20180108134418_b34-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180108134418_b35-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jchromb.2008.08.031","article-title":"GC-MS analysis of breath odor compounds in liver patients","volume":"875","author":"Van den Velde","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"key20180108134418_b36-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11096-008-9193-8","article-title":"Off-label drug use among hospitalised children: Identifying areas with the highest need for research","volume":"30","author":"Hsien","year":"2008","journal-title":"Pharm World Sci"},{"key":"key20180108134418_b37-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1358\/dof.2007.032.01.1068028","article-title":"Satavaptan","volume":"32","author":"Revill","year":"2007","journal-title":"Drug Fut"},{"key":"key20180108134418_b38-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1053\/jhep.2003.50274","article-title":"Nonselective beta-blockers plus nitrates in portal hypertension: An open question","volume":"37","author":"Merkel","year":"2003","journal-title":"Hepatology"},{"key":"key20180108134418_b39-etm-0-0-4210","first-page":"1","article-title":"Pharmacological associations in the primary\/prophylaxis of variceal bleeding in cirrhosis","volume":"21","author":"Merkel","year":"1998","journal-title":"Giornale Italiano di Endoscopia Digestiva"},{"key":"key20180108134418_b40-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"SIGNIFY Investigators: Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"key20180108134418_b41-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/1744-9987.12091","article-title":"Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients","volume":"17","author":"Rupnik","year":"2013","journal-title":"Ther Apher Dial"},{"key":"key20180108134418_b42-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.ajkd.2012.06.005","article-title":"Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial","volume":"60","author":"Fallahzadeh","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"key20180108134418_b43-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"key20180108134418_b44-etm-0-0-4210","first-page":"778","article-title":"Zastoupen\u00ed resitel\u016f studie FARIM: FARIM-FARmakoterapie po Infarktu Myokardu (Post-Myocardial Infarction Pharmacotherapy Study)","volume":"57","author":"Spinar","year":"2011","journal-title":"Vnitrni lekarstvi"},{"key":"key20180108134418_b45-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","article-title":"Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease","volume":"31","author":"Guney","year":"2009","journal-title":"Ren Fail"},{"key":"key20180108134418_b46-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/00365590801905943","article-title":"Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: An open, controlled, randomized study","volume":"42","author":"Tylicki","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"key20180108134418_b47-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key20180108134418_b48-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1097\/HJH.0b013e3282170ada","article-title":"Myocardial fibrosis and diastolic dysfunction in patients with hypertension: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)","volume":"25","author":"Muller-Brunotte","year":"2007","journal-title":"J Hypertens"},{"key":"key20180108134418_b49-etm-0-0-4210","first-page":"103","article-title":"Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients","volume":"59","author":"Orea-Tejeda","year":"2007","journal-title":"Rev Invest Clin"},{"key":"key20180108134418_b50-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1592\/phco.27.6.801","article-title":"Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure","volume":"27","author":"Cavallari","year":"2007","journal-title":"Pharmacotherapy"},{"key":"key20180108134418_b51-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-6143.2006.01588.x","article-title":"Renal allograft protection with angiotensin II type 1 receptor antagonists","volume":"7","author":"Tylicki","year":"2007","journal-title":"Am J Transplant"},{"key":"key20180108134418_b52-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/08037050600962968","article-title":"Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy","volume":"15","author":"Christensen","year":"2006","journal-title":"Blood Press"},{"key":"key20180108134418_b53-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.0000137118.47943.5C","article-title":"Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: Results of a randomized trial","volume":"110","author":"Ciulla","year":"2004","journal-title":"Circulation"},{"key":"key20180108134418_b54-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/clc.4960270315","article-title":"Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment-results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)","volume":"27","author":"Hallberg","year":"2004","journal-title":"Clin Cardiol"},{"key":"key20180108134418_b55-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000072820","article-title":"Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients","volume":"23","author":"el-Agroudy","year":"2003","journal-title":"Am J Nephrol"},{"key":"key20180108134418_b56-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","article-title":"Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"key20180108134418_b57-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gut.2010.210732","article-title":"Association of the G-protein and \u03b12-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: A randomised clinical trial","volume":"59","author":"Yang","year":"2010","journal-title":"Gut"},{"key":"key20180108134418_b58-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF02285102","article-title":"Effect of propranolol on urinary prostaglandin E2 excretion and renal interlobar arterial blood flow after furosemide administration in patients with hepatic cirrhosis","volume":"43","author":"Ljubici\u0107","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"key20180108134418_b59-etm-0-0-4210","first-page":"49","article-title":"Pharmacokinetic and pharmacodynamic characteristics of antihypertensive drugs in the treatment of hypertensive patients with chronic diseases of the liver","volume":"83","author":"Mikheeva","year":"2011","journal-title":"Ter Arkh"},{"key":"key20180108134418_b60-etm-0-0-4210","first-page":"95","article-title":"Pharmacokinetic and pharmacodynamic features of hypertensive drugs in treatment of patients with arterial hypertension associated with liver disease","author":"Mikheeva","year":"2010","journal-title":"Eksp Klin Gastroenterol"},{"key":"key20180108134418_b61-etm-0-0-4210","first-page":"413","article-title":"Non-invasive variceal pressure measurements: Validation and clinical implications","volume":"58","author":"Nevens","year":"1996","journal-title":"Verh K Acad Geneeskd Belg"},{"key":"key20180108134418_b62-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4065\/80.11.1501","article-title":"Influence of recent advances in medical management on clinical outcomes of cirrhosis","volume":"80","author":"Talwalkar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"key20180108134418_b63-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cgh.2011.06.004","article-title":"Surveillance for hepatocellular carcinoma in patients with cirrhosis","volume":"10","author":"Yang","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20180108134418_b64-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1440-1746.2008.05461.x","article-title":"Liver disease and the renin-angiotensin system: Recent discoveries and clinical implications","volume":"23","author":"Lubel","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"key20180108134418_b65-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1097\/MCG.0b013e318150d3c6","article-title":"Preventing first variceal hemorrhage in cirrhosis","volume":"41","author":"Albillos","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"key20180108134418_b66-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology: Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"46","author":"Garcia-Tsao","year":"2007","journal-title":"Hepatology"},{"key":"key20180108134418_b67-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/pgmj.2004.020446","article-title":"Management of portal hypertension","volume":"80","author":"Samonakis","year":"2004","journal-title":"Postgrad Med J"},{"key":"key20180108134418_b68-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14656566.5.2.349","article-title":"The role of vasoactive drugs in the treatment of oesophageal varices","volume":"5","author":"D'Amico","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"key20180108134418_b69-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/jlts.2003.50045","article-title":"Transjugular intrahepatic portosystemic shunts: An update","volume":"9","author":"Rosado","year":"2003","journal-title":"Liver Transpl"},{"key":"key20180108134418_b70-etm-0-0-4210","first-page":"57","article-title":"The sixth Carlos E. Rubio memorial lecture. Prevention and treatment of variceal hemorrhage","volume":"19","author":"Bosch","year":"2000","journal-title":"P R Health Sci J"},{"key":"key20180108134418_b71-etm-0-0-4210","first-page":"269","article-title":"Pharmacological treatment of portal hypertension","volume":"13","author":"Patch","year":"1995","journal-title":"Prog Liver Dis"},{"key":"key20180108134418_b72-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/hep.1840220145","article-title":"The treatment of portal hypertension: A meta-analytic review","volume":"22","author":"D'Amico","year":"1995","journal-title":"Hepatology"},{"key":"key20180108134418_b73-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-2007-1007300","article-title":"Management of ascites and renal failure in cirrhosis","volume":"14","author":"Forns","year":"1994","journal-title":"Semin Liver Dis"},{"key":"key20180108134418_b74-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Clin Liver Dis"},{"key":"key20180108134418_b75-etm-0-0-4210","first-page":"132","article-title":"Effects of propranolol on portal haemodynamics in patients with chronic liver disease","volume":"80","author":"Ohnishi","year":"1985","journal-title":"Am J Gastroenterol"},{"key":"key20180108134418_b76-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0168-8278(87)80012-0","article-title":"Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis","volume":"4","author":"Mastai","year":"1987","journal-title":"J Hepatol"},{"key":"key20180108134418_b77-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/jhep.2001.28231","article-title":"Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats","volume":"34","author":"Yoshiji","year":"2001","journal-title":"Hepatology"},{"key":"key20180108134418_b78-etm-0-0-4210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/gast.2001.26295","article-title":"Haemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension","volume":"121","author":"Schepke","year":"2001","journal-title":"Gastroenterology"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2017.4210\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T14:14:05Z","timestamp":1568902445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2017.4210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,3,9]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.3892\/etm.2017.4210"],"URL":"https:\/\/doi.org\/10.3892\/etm.2017.4210","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}